Overexpression of the transcriptional coregulators C-terminal binding proteins 1 and 2 (CtBP1 and 2) occurs in many human solid tumors and is associated with poor prognosis. CtBP modulates oncogenic gene expression programs and is an emerging drug target, but its oncogenic role is unclear. Consistent with this oncogenic potential, exogenous CtBP2 transformed primary mouse and human cells to anchorage independence similarly to mutant H-Ras. To investigate CtBP's contribution to in vivo tumorigenesis, Apc min/+ mice, which succumb to massive intestinal polyposis, were bred to Ctbp2 +/ − mice. CtBP interacts with adenomatous polyposis coli (APC) protein, and is stabilized in both APC-mutated human colon cancers and Apc min/+ intestinal polyps. Ctbp2 heterozygosity increased the median survival of Apc min/+ mice from 21 to 48 weeks, and reduced polyp formation by 90%, with Ctbp2 +/ − polyps exhibiting reduced levels of β-catenin and its oncogenic transcriptional target, cyclin D1. CtBP's potential as a therapeutic target was studied by treating Apc min/+ mice with the CtBP small-molecule inhibitors 4-methylthio-2-oxobutyric acid and 2-hydroxy-imino phenylpyruvic acid, both of which reduced polyposis by more than half compared with vehicle treatment. Phenocopying Ctbp2 deletion, both Ctbp inhibitors caused substantial decreases in the protein level of Ctbp2, as well its oncogenic partner β-catenin, and the effects of the inhibitors on CtBP and β-catenin levels could be modeled in an APC-mutated human colon cancer cell line. CtBP2 is thus a druggable transforming oncoprotein critical for the evolution of neoplasia driven by Apc mutation.
INTRODUCTION
C-terminal binding proteins 1 and 2 (CtBP1 and 2) are evolutionarily conserved transcriptional coregulators that interact with both DNA-binding transcription factors and chromatin remodelers, such as histone methyltransferases and histone deacetylases, to activate or repress gene expression. 1 Both CtBP1 and 2 are found overexpressed in a number of solid tumors, including colorectal, prostate, ovarian and breast cancer, with overexpression correlating with lower overall median survival, leading to a proposed role of CtBP as a driver oncogene in solid tumors. [2] [3] [4] [5] [6] CtBP's potential tumorigenic capabilities arise from its oncogenic transcriptional reprogramming of cells that includes (1) repression of proapoptotic genes such as Bik, Puma, Noxa and PERP; (2) repression of tumor suppressors including PTEN, p16
Ink4a , p15
Ink4b and p21 waf1/cip1 ; and (3) activation of the metastasis associated gene TIAM-1 that promotes migration and invasion.
2,7-10 CtBP's activation of migration/invasion combined with repression of epithelial genes such as E-cadherin and keratin-8 additionally promotes EMT, which may be linked to metastasis and poor outcomes in CtBP-overexpressing malignancies. 2, [8] [9] [10] CtBP is also an emerging target in cancer as it encodes a druggable dehydrogenase domain for which first-and secondgeneration inhibitors have already been identified. 6, 11 Although multiple indirect lines of evidence suggest that CtBP has a role in tumorigenesis, its designation as a driver of cellular transformation and oncogenesis in vivo has yet to be established, aside from one report demonstrating lower efficiency of Ras transformation of murine embryonic fibroblasts (MEFs) doubly homozygous for CtBP1 and 2. 8 For this reason, we initiated a set of experiments designed to determine the oncogenic potential of CtBP in vitro using both murine and human fibroblasts, and in vivo using the Apc min/+ mouse intestinal polyposis model. We demonstrate that CtBP2 can transform primary MEFs by cooperating with large T-antigen (LT) of simian virus 40 (SV40), and can cooperate with hTERT, LT and SV40 small T-antigen (ST) to induce migration/ invasion and anchorage-independent growth in BJ human foreskin fibroblasts. Haploinsufficiency of Ctbp2 in Apc min/+ mice resulted in a marked decrease in intestinal polyp number and a marked increase in survival. Furthermore, treatment of Apc min/+ mice with the Ctbp2 small-molecule inhibitors 4-methylthio-2-oxobutyric acid (MTOB) and 2-hydroxy-imino phenylpyruvic acid (HIPP) resulted in a significant decrease in the polyp number. Thus, Ctbp2 has a critical role in driving the min phenotype, and moreover, is a novel drug target in neoplasia resulting from Apc loss.
RESULTS AND DISCUSSION
CtBP2 in combination with LT transforms primary MEFs Given CtBP's proposed role as an oncogene, we explored its ability to transform primary MEFs, which require introduction of cooperating oncogenes that can inactivate the p53/Rb tumor suppressor pathways (such as SV40 LT or human papillomavirus E6/E7) and drive proliferation (such as activated Ras). 12 We hypothesized that CtBP2 could act as an activating oncogene that when combined with LT could induce transformation. Early passage MEFs stably expressing LT (MEF-LT; Supplementary Figure 1A ) were therefore infected with empty vector (EV) control (pBABE-puro-EV), V5-CtBP2 (pBABE-puro-V5-CtBP2) or positive control H-RasV12 (pBABE-puro-H-RasV12) retroviruses (Figure 1a) , and expression of V5-CtBP2 (~2-fold over endogenous Ctbp2) and H-Ras confirmed by immunoblot (Figure 1a and Supplementary Figure 1B ). Each cell line was then plated in soft agar, and analyzed for colony formation after 3 weeks. Both H-RasV12 and CtBP2 cooperated with LT to induce significantly more colonies than control cells (P o 0.05) (Figure 1b) , consistent with a rodent cell-transforming ability for CtBP2.
As part of the characterization of its oncogenic properties, CtBP is known to regulate positively migration/invasion in human cancer cell lines, which is a correlate of its presumed prometastatic functions.
2,9-10 However, it is not known whether CtBP can induce migration/invasion in primarily transformed cells. To understand if the combination of CtBP2 and LT could cooperate to induce invasion/migration of MEFs, control, CtBP2 or H-RasV12-expressing MEF-LT cells were seeded onto Matrigel-coated well inserts. CtBP2-expressing MEF-LT cells displayed a robust invasive phenotype, with a near sixfold increase over EV control (P o 0.01), and a threefold increase over the activated H-Ras positive control (Figure 1c) , consistent with prior observations in cell lines, and also highlighting the distinct role for CtBP in driving invasion/migration in cells apart from the various transforming properties of LT related to p53 and Rb inactivation.
CtBP2 cooperatively transforms human fibroblasts
We next determined whether CtBP2 also possessed human primary cell transformation potential. Unlike MEFs, transformation of human fibroblasts requires expression of the catalytic subunit of telomerase (hTERT), inactivation of tumor suppressors p53 and Rb (such as by LT), inactivation of PP2A signaling and the addition of an activating oncogene such as mutant Ras. 12 The viral oncoproducts of the SV40-early region, LT and ST, facilitate human cell transformation through binding and inactivation of p53/Rb and PP2A, respectively. With this in mind, we designed experiments to determine whether CtBP2 could transform BJ human foreskin fibroblasts and serve as an activating oncogene when combined with hTERT, LT and ST.
BJ-hTERT cells were first infected with an SV40-early region genomic retrovirus (expressing both LT and ST) and selected with zeocin for 2 weeks (Supplementary Figure 1C) . Following selection, BJ-hTERT-LT-ST (hereafter known as BLS) cells were subsequently transduced with either EV control, V5-CtBP2 or H-RasV12 retroviruses and expression of V5-CtBP2 (~2.5-fold over endogenous CtBP2) and H-Ras confirmed by immunoblot (Figure 1d and Supplementary Figure 1B) . Each cell line was subsequently assayed for anchorage-independent growth and induction of migration/invasion (Figures 1e and f) . When assayed for growth in soft agar, BLS-CtBP2 cells formed significantly more colonies than vector-transduced BLS cells (twofold; P o 0.05), similar to BLS-HRas cells (Figure 1e) . As with the MEFs, BLS-CtBP2 cells exhibited a twofold higher invasion/migration index than BLS-H-Ras cells and a~4-fold higher index versus control cells (P o 0.01; Figure 1f ). These data suggest that like H-RasV12, CtBP2 acts as an activating oncogene to transform telomerase-expressing human cells following loss of cell-cycle regulation and p53 function via LT/ST. Ctbp2 haploinsufficiency in Apc min/+ mice leads to increased survival and decreased polyposis Mutations in the APC tumor suppressor gene occur in roughly 70% of human colorectal cancers 13 and inheritance of a single truncated allele of APC is the cause of the human syndrome familial adenomatous polyposis (FAP), characterized by massive colonic polyposis and early-onset colon cancer.
14 A similarly mutated Apc gene in the min mouse model of FAP results in the rapid onset of intestinal polyposis and premature death due to obstruction. 15 The Apc min model was especially well suited to study CtBP-driven tumorigenesis due to known targeting of CtBP for proteasomal degradation by the APC complex. 16, 17 Indeed, multiple studies have linked increased levels of CtBP to loss or mutation of APC in human cancers, including one study that reported elevated levels of CtBP in polyps obtained from FAP patients harboring mutant APC. 16, 17 Having shown that CtBP2 can drive transformation of murine and human fibroblasts in vitro, we sought to understand the role of CtBP2 in a tumor model that incorporated its overexpression, and where genetic knockout could be used to endogenously modulate the cellular level of Ctbp2.
As homozygous deletion of Ctbp2 is embryonically lethal, mice killed at 21 weeks, suggesting that the onset for polyp formation in these mice, when it occurs, is delayed till later than 21 weeks (Figures 2c and d) .
Ctbp2 drives β-catenin accumulation and cyclin D1 expression in Apc min/+ polyps
Apc truncation mutations such as the one harbored by the min mouse result in the loss of β-catenin regulation, leading to increased β-catenin levels in the nucleus and activation of downstream transcription of target genes such as c-myc and cyclin D1. 19 Analysis of β-catenin protein levels in polyps of each genotype revealed higher levels, as expected, in polyp tissue BJ-hTERT-blast cells (tested and confirmed mycoplasma free) were kindly provided by L Litovchick and were maintained in Eagle's minimal essential medium (Gibco, Grand Island, NY, USA) supplemented with 10% fetal bovine serum (FBS) and incubated at 37°C in a humidified, 5% CO 2 environment. Primary MEFs were obtained from mouse embryos at age E10.5. After harvest, cells were plated onto gelatin-coated plates and left to attach for 24 h before use in assays. MEFs were maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% FBS, 5% MEM non-essential amino acids (Life Technologies, Grand Island, NY, USA), and 5% L-glutamine (Life Technologies). MEF cells infected with CtBP2 or H-RasV12-expressing retroviruses were selected for 1 week using 1 μg/ml puromycin. MEF cells infected with LT (cDNA)-expressing retrovirus were selected for 2 weeks using 200 μg/ml zeocin. BJ-hTERT cells were serially infected with specified plasmids and selected with puromycin (CtBP2, H-Ras) and/or zeocin (LT/ST genomic construct). For invasion assays, cells were plated into 6-well Matrigel-coated invasion chambers (Corning, Bedford, MA, USA). After 24 h, chambers were washed in phosphate-buffered saline (PBS), fixed in methanol for 20 min and stained in Giemsa solution overnight. For soft-agar assays, cells expressing specified plasmids were mixed into 0.3% noble agar and poured onto 60 mm plates containing a solidified bottom layer of 0.6% noble agar. Plates were left to form colonies for 21 days. For western blotting, cells were washed in cold PBS and lysed in RIPA buffer (150 mM NaCl, 50 mM Tris HCl, pH 8.0, 1.7% NP-40, 0.17% sodium dodecyl sulfate (SDS), 0.5% Na-deoxycholate monohydrate, 5 mM EDTA) containing 1 tablet of complete Mini Protease Inhibitor Cocktail/10 ml (Roche, Indianapolis, IN, USA). Lysates were cleared of insoluble material by centrifugation at 15 000 r.p.m. Proteins (30 μg) were loaded onto a Bis-Tris 4-12% gel containing NuPAGE MES buffer. pBABE-zeo-LargeTgenomic (expressing LT and ST), pBABE-zeo-LargeTcDNA and pBABE-puro-H-Ras were obtained from Addgene (Cambridge, MA, USA). CtBP2 cDNA was cloned into pBABE-puro-V5 to produce pBABEpuro-CtBP2V5. Pc-CtBP2V5 has been previously described. 20 Antibodies used were as follows: anti-CtBP2 E-16 (Santa Cruz Biotechnologies, Santa Cruz, CA, USA); anti-SV40-LT Pab 101 (Santa Cruz Biotechnologies); anti-SV40-ST Pab 419 (Santa Cruz Biotechnologies); anti-Actin (SigmaAldrich, St Louis, MO, USA); anti-Ras C-20 (Santa Cruz Biotechnologies). Figure 2B) , suggesting that Ctbp2, or a transcriptional target of Ctbp2, post-transcriptionally regulates β-catenin protein abundance in intestinal polyps. To understand what effect lowered Ctbp2 levels could have on downstream pathways of known importance in APC-defective tumors, we performed quantitative PCR analysis on mRNA derived from normal and polyp tissue from each genotype, using primers against targets known to be active in Wnt signaling, including c-myc and cyclin D1 (Figure 2f ). Although mRNA levels of c-myc did not show a significant change in expression levels between normal or polyp tissue, or between Ctbp2 wt or +/ − strains, levels of cyclin D1 were significantly elevated in polyp tissue compared with normal tissue in Apc min/+ /Ctbp2 +/+ mice (P o0.05), and furthermore, were significantly elevated over levels found in polyps from Apc min/+ /Ctbp2 +/ − mice (P o 0.05; Figure 2f ). Figure 2i ). These data suggest that the levels of Ctbp2 regulate induced β-catenin levels in polyps, and furthermore, suggest that Ctbp2 directly, or indirectly through β-catenin, regulates the expression of cyclin D1, a known oncogenic driver of polyposis in APC mutant phenotypes. Figures 3a and b) . Surprisingly, mice that received injections of MTOB and HIPP retained a more normal intestinal morphology and exhibited a 56% reduction (21/mouse, Po 0.0001) and a 69% reduction (15/mice P o0.0001) in polyp number, respectively (Figures 3a and b) .
Targeting CtBP in
As Ctbp2 haploinsufficiency resulted in a decrease in β-catenin protein levels in the few polyps detected in Apc min/+ /Ctbp2 +/ − mice, polyps were harvested from Apc min/+ mice treated with MTOB or HIPP to determine if pharmacological inhibition of Ctbp2 also resulted in β-catenin depletion. Compared with polyps arising in vehicle-treated Apc min/+ mice, MTOB-and HIPP-treated polyps indeed did display markedly reduced levels of Ctbp2 and β-catenin protein similar to that seen in Apc min/+ /Ctbp2 +/ − mice (Figure 3c ). Finally, to determine if CtBP inhibitor actions toward CtBP2 and β-catenin in Apc min/+ polyps were mirrored in human colon cancer cells harboring mutant APC, we treated COLO320 cells (which have an APC truncation that closely mirrors the min truncation) with MTOB or HIPP. Similar to Apc min/+ polyps, treatment of COLO320 cells with MTOB or HIPP resulted in modest but reproducible decreases of both CtBP2 and β-catenin protein levels (Figure 3d) . Thus, CtBP inhibitors may reduce polyposis by driving reductions in CtBP2 and β-catenin expression, consistent with the effects observed by reducing Ctbp2 gene dosage by 50%, and can induce similar effects in an APC-mutated human colon cancer cell line.
Our data firmly establish Ctbp2 as a gatekeeper in Apc-related tumorigenesis, where even modest 50% reductions in Ctbp2 abundance, as in Apc min/+ /Ctbp2 +/ − mice, or its partial chemical inhibition by MTOB or HIPP, reveal a sharp threshold effect for sufficiency of Ctbp2 levels for polyp formation. β-Catenin protein levels tracked closely with Ctbp2 expression levels in both normal and tumor tissues of Apc min mice, suggesting a direct relationship between Ctbp2 and β-catenin abundances. This phenomenon is almost certainly related to recent findings that CtBP induces mutant APC oligomerization in human colon cancer cells, which contributes to β-catenin stabilization by blocking APC/ β-catenin interaction. 20 Indeed, selection for the length of retained APC alleles in FAP, the syndrome modeled in Apc min/+ , invariably results in retention of CtBP interaction domains by the mutant APC protein. 20 Our work also establishes CtBP inhibition with dehydrogenase substrate competitive inhibitors as safe and effective for the reduction of Apc min-mediated polyposis. CtBP inhibitors reduce cellular CtBP2 abundance, at least in Apc-mutated mouse intestine or human APC-mutated colon cancer cells, with the likely result of reduced β-catenin levels that phenocopies β-catenin reductions in . Sample sizes for each cohort were estimated to ensure 80% power. All mouse experiments were performed with approval of the VCU IACUC. To confirm desired genotypes of study mice, the following primers were used for end point PCR: Apc min/+ , F-5′-GGGAAGTTTAGACAGTTCTCGT-3′ and R-5′-TGTTGGATGGTAAGCACTGAG-3′, Mut-5′-AGACAGAA GTTAGGAGAGAGAGC-3′ and WT-5′-AGACAGAAGTTTGGAGAGAGAGC-3′. Ctbp2 +/ − Internal Con, F-5′-CAAATGTTGCTTGTCTGGTG-3′ and R -5′-GTCAGTCGAGTGCACAGTTT-3′, Mut F-5′-CCAGTGGGGATCGACGGTATC-3′, Mut R-5′-CACTCCAACGCAGCACCATC-3′. Survival curves were generated from mice that were monitored daily and killed when moribund. In the case of Apc min/+ /Ctbp2 +/ − mice in the survival study, six mice were killed before humane end point (while still healthy, counted as censored) to obtain intestinal tissues (2 at 21 weeks, 3 at 37 weeks and 1 at 38 weeks). Ctbp2 +/+ intestinal tissues, used for polyp number, protein, mRNA and histopathological analysis, were obtained at the time of death (or humane end point). Whole intestines were surgically removed, perfused with PBS and analyzed for polyp number. For hematoxylin and eosin (H&E) staining, intestines were cut into 4-5 cm strips and perfused with PBS, followed by 10% formalin solution. Once clean, strips were cut longitudinally on blotting paper and Swiss-roll preparations were stained with H&E. For protein and mRNA analysis, polyps (and adjacent normal tissue) were cut into roughly 1 cm 3 pieces and ground by mortar and pestle, followed by resuspension in either RIPA supplemented with protease inhibitors for protein analysis, or RNAeasy buffer (Qiagen, Hilden, Germany) to obtain mRNA. To examine changes of protein level and localization of cyclin D, CtBP2 and β-catenin, immunohistochemical analysis was performed using mouse anticyclin D (72-13G; Santa Cruz Biotechnology), β-catenin and CtBP2 (clone 14 and 16, respectively; BD Biosciences, San Jose, CA, USA); each were used at a 1:50 dilution. The paraffin-embedded tissue was deparaffinized in xylene and rehydrated through graded ethanol, followed by antigen retrieval using 10 mM sodium citrate buffer (pH 6.0) for 15 min. The slides were allowed to cool to room temperature for 30 min. After the slides were washed, exogenous peroxidase activity was blocked by incubating the slides in 3% peroxidase for 20 min. The slides were then washed, blocked in 5% normal goal serum-PBS (NGS-PBS) for 60 min at room temperature, and incubated overnight at 4°C in primary antibody diluted in 5% NGS-PBS. Following primary antibody incubation and washing with PBS, the slides were incubated in secondary horse radish peroxidase (HRP) anti-mouse IgG reagent (Agilent Technologies, Santa Clara, CA, USA) at room temperature for 1 h, washed with PBS and then detected using EnVision+ Kit (Agilent Technologies). Counterstaining with hematoxylin was performed and the slides were dehydrated through graded ethanol and then xylene and mounted with Entellan (Electron Microscopy Sciences, Hatfield, PA, USA). Total cell RNA was purified using RNeasy (Qiagen) according to the manufacturer's suggested protocol. cDNA was generated using Affinity Script RT (Agilent Technologies). One microliter of cDNA was amplified in triplicate using SYBRgreen and the specified primers. Q-PCR primers: c-myc (F, 5′-AACAGGAACTATGACCTCG-3′ and R, 5′-AGCAGCTCGAATTTCTTC-3′), cyclin D1 (F, 5′-CAGACGTTCAGAACCAGATTC-3′ and R, 5′-CCCTCCAATAGCAGCGAAAAC-3′) and GAPDH (F, 5′-AAGGTCATCCCAGAGCTGAA-3′ and R, 5′-CTGCTTCACCACCTTCTT-3′). . Sample sizes for each cohort were estimated to ensure 80% power. Mice with the correct genotype were randomly assigned to the vehicle or drug group. COLO320 cells were obtained from ATCC (Manassas, VA, USA; confirmed mycoplasma free) and maintained in RPMI-1640 supplemented with 10% FBS and incubated at 37°C in a humidified, 5% CO 2 environment.
